Changes of the serum antibiotic levels during open heart surgery (ceftazidim, ciprofloxacin, clindamycin).
BACKGROUND
Wound, mediastinal and intracardiac infections are still very serious complications of open-heart surgery. The incidence of it is still in the range of 0.4%-5%. The aims of our study were to assess the adequacy of regimen using ceftazidim (CTZ), ciprofloxacin (CPF) and clindamycin (CLIN) as prophylactic antibiotics and to verify whether cardiopulmonary bypass (CPB) can modify the time of antibiotic serum concentrations. That is why the serum levels of them were measured during open heart procedures.


METHODS
The prospective study comprised 75 consequent coronary patients randomized in to three groups receiving 1 g of CTZ or 400 mg of CPF or 900 mg of CLIN i.v. with anesthesia induction. Routine coronary surgery with left internal mammary artery harvesting, moderate body hypothermic (30 degrees C) CPB with crystaloid cardioplegia was performed. Serum antibiotic levels were determined before application, with skin incision, prior CPB induction, after cardioplegia infusion, every 20 minutes of CPB, prior end of CPB, in time of chest closure. Conventional cylinder-plate microbiological assay was used for antibiotic level measurement.


RESULTS
All serum antibiotic concentrations showed a sharp decrease immediately after starting CPB and lasted until CPB ended. After initiating of CPB after cardioplegia administration serum concentrations of CTZ (105 min after initial dose) decreased by, on average 55%, CPF (97 min) by 42% and CLIN (116 min) by 78%.


CONCLUSIONS
CPB can modify the time course of antibiotic serum concentrations. The serum levels of CTZ at the end of the longest procedures were found to be below the MICs for some of the suspected pathogens. We recommend to use higher antibiotic doses for prophylaxis and to administer the second dose with protamin sulphate to obtain maximum concentration in newly formed blood clots.
Department of Cardiosurgery, Charles University, Faculty of Medicine in Hradec Králové, Prague. vlonsky@usa.net
V
V
Lonský
J
J
Dominik
J
J
Mand'ák
E
E
Pozlerová
M
M
Hejzlar
V
V
Lonská
M
M
Marsíková
J
J
Kubícek
M
M
Snítilová
D000900:Anti-Bacterial Agents / Q000097:blood*; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000097:blood; D019072:Antibiotic Prophylaxis; D002315:Cardiopulmonary Bypass; D002442:Ceftazidime / Q000097:blood; D002511:Cephalosporins / Q000008:administration & dosage / Q000097:blood; D002939:Ciprofloxacin / Q000097:blood; D002981:Clindamycin / Q000097:blood; D001026:Coronary Artery Bypass; D006801:Humans; D011446:Prospective Studies
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002511:Cephalosporins; D002981:Clindamycin; D002939:Ciprofloxacin; D002442:Ceftazidime